Clinical Trial Update: Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial is evaluating a flexible dosing schedule of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer, with status currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Phase 2 | Status: RECRUITING